BPA
LYRA

Beacon Pointe Advisors’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Beacon Pointe Advisors’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,542
Closed -$19.8K – 1249
2024
Q3 		$19.8K Buy
+1,542
New +$22.7K ﹤0.01% 1214

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Beacon Pointe Advisors's LYRA Position: Q4 2024 in Review

Beacon Pointe Advisors sold out of LYRA THERAPEUTICS INC (LYRA) in Q4 2024, closing a stake of 1,542 shares — an estimated $19.8K sold.

Beacon Pointe Advisors first reported a position in LYRA in Q3 2024 and held it in 1 quarter. The position peaked at $19.8K in Q3 2024. 54 funds tracked by Wall St. Rank hold LYRA as of Q4 2024.

  • Beacon Pointe Advisors reported no remaining LYRA THERAPEUTICS INC position as of Q4 2024 after selling out during the quarter.
  • Beacon Pointe Advisors sold 1,542 LYRA THERAPEUTICS INC shares in Q4 2024, an estimated $19.8K.
  • Beacon Pointe Advisors first reported a position in LYRA THERAPEUTICS INC in Q3 2024 and held it in 1 quarter.
  • Beacon Pointe Advisors's LYRA THERAPEUTICS INC position peaked at $19.8K in Q3 2024.
  • 54 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q4 2024.

Based on Beacon Pointe Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.